UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 125

of 'Prognostic and predictive factors in early, nonmetastatic breast cancer'

125
TI
Clinical application of the 70-gene profile: the MINDACT trial.
AU
Cardoso F, Van't Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ
SO
J Clin Oncol. 2008;26(5):729.
 
The 70-gene profile is a new prognostic tool that has the potential to greatly improve risk assessment and treatment decision making for early breast cancer. Its prospective validation is currently ongoing through the MINDACT (Microarray in Node-Negative Disease May Avoid Chemotherapy) trial, a 6,000-patient randomized, multicentric trial. This article reviews the several steps in the development of the profile from its discovery to its clinical validation.
AD
Jules Bordet Institute, Blvd de Waterloo, 125, 1000 Brussels, Belgium.
PMID